Hepatitis C viral load, genotype 3 and interleukin-28B CC genotype predict mortality in HIV and hepatitis C-coinfected individuals

AIDS

Volumn 26, Issue 12, 2012, Pages 1509-1516

  Clausen, Louise Nygaard ^a,b   Astvad, Karen ^a   Ladelund, Steen ^a   Larsen, Mette Vang ^a   Schønning, Kristian ^a   Benfield, Thomas ^a,b  

^a Mental Health Services CPH   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

chronic inflammation; disease burden; HIV exposure group; time updated survival analysis

Indexed keywords

INTERLEUKIN 28B; VIRUS RNA;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; OBSERVATIONAL STUDY; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD;

ADULT; AGED; CD4 LYMPHOCYTE COUNT; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; VIRAL LOAD;

EID: 84864289855     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283553581     Document Type: Article

References (49)

1. Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 2011; 8:12-22.
2. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36:S21-S29.
3. Daar ES, Lynn H, Donfield S, Gomperts E, Hilgartner MW, Hoots WK, et al. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr 2001; 26:466-472.
4. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001; 183:1112-1115.
5. Hisada M, Chatterjee N, Kalaylioglu Z, Battjes RJ, Goedert JJ. Hepatitis C virus load and survival among injection drug users in the United States. Hepatology 2005; 42:1446-1452.
6. Fanning L, Kenny E, Sheehan M, Cannon B, Whelton M, O'Connell J, et al. Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. Hepatology 1999; 29:904-907.
7. Goedert JJ, Hatzakis A, Sherman KE, Eyster ME. Lack of association of hepatitis C virus load and genotype with risk of end-stage liver disease in patients with human immunodeficiency virus coinfection. J Infect Dis 2001; 184:1202-1205.
8. Freeman AJ, Law MG, Kaldor JM, Dore GJ. Predicting progression to cirrhosis in chronic hepatitis C virus infection. J Viral Hepat 2003; 10:285-293.
9. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349:825-832.
10. Seeff LB. Natural history of hepatitis C. Am J Med 1999; 107:10S-15S.
11. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284:450-456.
12. Daar ES, Lynn H, Donfield S, Gomperts E, O'Brien SJ, Hilgartner MW, et al. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis 2001; 183:589-595.
13. Yee TT, Griffioen A, Sabin CA, Dusheiko G, Lee CA. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 2000; 47:845-851.
14. Sabin CA, Telfer P, Phillips AN, Bhagani S, Lee CA. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis 1997; 175:164-168.
15. Yoo TW, Donfield S, Lail A, Lynn HS, Daar ES. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J Infect Dis 2005; 191:4-10.
16. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33:1358-1364.
17. de Mendoza MC, Soriano V. The role of hepatitis C virus (HCV) in mitochondrial DNA damage in HIV/HCV-coinfected individuals. Antivir Ther 2005; 10 (Suppl 2):M109-M115.
18. Day CP, James OF. Steatohepatitis: a tale of two 'hits'? Gastroenterology 1998; 114:842-845.
19. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126:586-597.
20. Labarga P, Soriano V, Caruz A, Poveda E, Di LF, Hernandez-Quero J, et al. Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. AIDS 2011; 25:761-766.
21. Clausen LN, Weis N, Astvad K, Schonning K, Fenger M, Krarup H, et al. Interleukin-28B polymorphisms are associated with hepatitis C virus clearance and viral load in a HIV-1-infected cohort. J Viral Hepat 2011; 18:e66-e74.
22. Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, Scherzer R, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 2010; 55:316-322.
23. Obel N, Engsig FN, Rasmussen LD, Larsen MV, Omland LH, Sorensen HT. Cohort profile: the Danish HIV cohort study. Int J Epidemiol 2009; 38:1202-1206.
24. Juel K, Helweg-Larsen K. The Danish registers of causes of death. Dan Med Bull 1999; 46:354-357.
25. Krarup HB, Moller JM, Christensen PB, Fuglsang T, Ingerslev J, Arnfred T, et al. Haemophilic patients with hepatitis C have higher viral load compared to other well defined patient groups. J Viral Hepat 2000; 7:435-439.
26. Murphy DG, Willems B, Deschenes M, Hilzenrat N, Mousseau R, Sabbah S. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5′ untranslated region sequences. J Clin Microbiol 2007; 45:1102-1112.
27. Nijman IJ, Kuipers S, Verheul M, Guryev V, Cuppen E. A genome-wide SNP panel for mapping and association studies in the rat. BMC Genomics 2008; 9:95.
28. Levesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010; 340:b5087.
29. Cordell HJ, Clayton DG. Genetic association studies. Lancet 2005; 366:1121-1131.
30. Rostgaard K. Methods for stratification of person-time and events: a prerequisite for Poisson regression and SIR estimation. Epidemiol Perspect Innov 2008; 5:7.
31. Rosenberg PM, Farrell JJ, Abraczinskas DR, Graeme-Cook FM, Dienstag JL, Chung RT. Rapidly progressive fibrosing cholestatic hepatitis: hepatitis C virus in HIV coinfection. Am J Gastroenterol 2002; 97:478-483.
32. Klenerman P, Kim A. HCV-HIV coinfection: simple messages from a complex disease. PLoS Med 2007; 4:e240.
33. Klenerman P, Hill A. T cells and viral persistence: lessons from diverse infections. Nat Immunol 2005; 6:873-879.
34. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954.
35. Fujie H, Yotsuyanagi H, Moriya K, Shintani Y, Tsutsumi T, Takayama T, et al. Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. J Med Virol 1999; 59:141-145.
36. Barreiro P, Martin-Carbonero L, Nunez M, Rivas P, Morente A, Simarro N, et al. Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3. Clin Infect Dis 2006; 42:1032-1039.
37. Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Mullhaupt B, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51:655-666.
38. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of allcause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9:509-516.
39. Zeuzem S. Forewarned is forearmed. J Hepatol 2009; 51:626-627.
40. Nunez M, Miralles C, Berdun MA, Losada E, Aguirrebengoa K, Ocampo A, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIVinfected patients: the PRESCO trial. AIDS ResHum Retroviruses 2007; 23:972-982.
41. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIVinfected patients. N Engl J Med 2004; 351:438-450.
42. Barreiro P, Pineda JA, Rallon N, Naggie S, Martin-Carbonero L, Neukam K, et al. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. J Infect Dis 2011; 203:1629-1636.
43. Omland LH, Jepsen P, Skinhoj P, Jorgensen HL, Munster AM, Bangsborg J, et al. The impact of HIV-1 co-infection on longterm mortality in patients with hepatitis C: a population-based cohort study. HIV Med 2009; 10:65-71.
44. Omland LH, Krarup H, Jepsen P, Georgsen J, Harritshoj LH, Riisom K, et al. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol 2010; 53:36-42.
45. Omland LH, Jepsen P, Weis N, Christensen PB, Laursen AL, Nielsen H, et al. Mortality in HIV-infected injection drug users with active vs cleared hepatitis C virus-infection: a populationbased cohort study. J Viral Hepat 2010; 17:261-268.
46. Weis N, Lindhardt BO, Kronborg G, Hansen AB, Laursen AL, Christensen PB, et al. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Clin Infect Dis 2006; 42:1481-1487.
47. Chen TY, Ding EL, Seage Iii GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009; 49:1605-1615.
48. Deng LP, Gui XE, Zhang YX, Gao SC, Yang RR. Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. World J Gastroenterol 2009; 15:996-1003.
49. Kowalska JD, Friis-Moller N, Kirk O, Bannister W, Mocroft A, Sabin C, et al. The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology 2011; 22:516-523.